March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
January 2026 in “Food Science and Human Wellness” Krill oil may help reduce prostate enlargement and growth.
January 2026 in “Springer Link (Chiba Institute of Technology)” Silver nanoparticles from Mitracarpus scaber protect the liver and reduce prostate enlargement.
January 2026 in “Journal of Pharmacy & Bioresources” Many patients with benign prostatic hyperplasia experience high anxiety and residual symptoms, needing better anxiety management.
December 2025 in “Molecular Pharmaceutics” Combining tadalafil and finasteride improves their solubility and effectiveness.
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
June 2025 in “International Journal of Clinical Medical Research” Healthcare professionals need better training and systems for drug interaction reporting, injectable vitamin B12 helps tingling, oral helps numbness, probiotics may help ulcerative colitis, and more research is needed on Post-Finasteride Syndrome.
March 2025 in “MAEDICA – a Journal of Clinical Medicine” COVID-19 may worsen symptoms of benign prostatic hyperplasia (BPH).
December 2024 in “Frontiers in Endocrinology” Continued research and awareness are needed to improve treatments for androgen-dependent diseases.
September 2024 in “LUTS Lower Urinary Tract Symptoms” People with hair loss may have worse urinary symptoms due to an enlarged prostate.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
May 2024 in “KIU journal of health science” Kolaviron and quercetin may help treat prostate issues.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
January 2024 in “Journal of Applied Health Sciences and Medicine” Nephrolepis biserrata may improve fertility and reduce prostate issues in males.
December 2023 in “Bulletin of Pharmaceutical Sciences Assiut” Herbal products for benign prostate hypertrophy need better quality checks to ensure safety and effectiveness.
August 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride effectively treats hair loss and prostate issues.
July 2023 in “International Journal of Molecular Sciences” Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
April 2023 in “Jordan Medical Journal” Men with male pattern baldness are more likely to have benign prostatic hyperplasia.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
September 2021 in “The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy” COVID-19 worsens urinary symptoms in men with benign prostatic hyperplasia, requiring careful treatment management.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
Pumpkin roots contain compounds like Alpha-spinasterol, squalene, and palmitic acid, which may have health benefits like reducing depression, treating certain cancers, and having antibacterial properties.
September 2020 in “Scientific periodicals of Ukraine” "Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.